Mirum Pharmaceuticals 2025 sales rise

Mirum Pharmaceuticals

25/02/2026 21:11

Overview

Rare disease company reported 2025 net product sales of $521 mln, up from 2024

Company expects 2026 global net product sales of $630 mln to $650 mln

Company completed acquisition of Bluejay Therapeutics, adding brelovitug for HDV

Outlook

Mirum expects 2026 global net product sales of $630 mln to $650 mln

Volixibat VISTAS study topline data expected in Q2 2026

LIVMARLI EXPAND study topline data expected in Q4 2026

Result Drivers

LIVMARLI SALES GROWTH - LIVMARLI net product sales increased 69% year-over-year in the U.S., contributing significantly to 2025 revenue growth

GLOBAL EXPANSION - Expanded commercial access to 33 countries, enhancing global sales reach

BLUEJAY ACQUISITION - Acquisition of Bluejay Therapeutics added brelovitug for HDV, enhancing pipeline

Company press release: ID:nBwc886mla

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Product Sales
$148.93 mln
Q4 Net Income
-$5.73 mln
Q4 Operating Expenses
$153.50 mln
Q4 Operating Income
-$4.57 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Mirum Pharmaceuticals Inc is $112.50, about 4.7% above its February 24 closing price of $107.48

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)